Cipher Pharmaceuticals Inc.
Cipher Pharmaceuticals Inc. (CPH.TO) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
cph.to · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Cipher Pharmaceuticals Inc. (CPH.TO) measures how much investors pay for each dollar of the company's trailing earnings. CPH.TO's current PE ratio of 9.86x is calculated by dividing its stock price of $16.84 by its TTM earnings per share of $1.22. +11.9% elevated vs 5Y avg 8.8x
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2006 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 13 fiscal years · Front-end computedMinQ1 · 25%10.1x
MedianQ3 · 75%516.6x
Max
At 9.86x, CPH.TO's current P/E is within its average historical range over the past 13 fiscal years.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Drug Manufacturers - Specialty & Generic · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Cipher Pharmaceuticals Inc.You CPH.TO | $428M | 9.86x | — | $1.22 |
 Aurora Cannabis Inc. ACB.TO | $267M | 217.30x | — | $0.03 |
 Spectral Medical Inc. EDT.TO | $405M | N/A | — | -$0.17 |
 Fennec Pharmaceuticals Inc. FRX.TO | $364M | N/A | — | -$0.36 |
 Knight Therapeutics Inc. GUD.TO | $844M | N/A | — | -$0.05 |
 High Tide Inc. HITI.V | $283M | N/A | — | -$0.62 |
 Jushi Holdings Inc. JUSH.CN | $140M | N/A | — | -$0.35 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | 10.05x | $1.09 | -52.8% | |
2024-12-31 FY2024 | 21.31x | $0.47 | +308.1% | |
2023-12-31 FY2023 | 5.22x | $0.80 | +95.3% | |
2022-12-31 FY2022 | 2.67x | $1.06 | -44.3% | |
2021-12-31 FY2021 | 4.80x | $0.29 | +10.6% | |
2020-12-31 FY2020 | 4.34x | $0.17 | -54.6% | |
2019-12-31 FY2019 | 9.56x | $0.12 | -84.5% | |
2018-12-31 FY2018 | 61.78x | $0.02 | +172.9% | |
2017-12-31 FY2017 | 22.64x | $0.17 | — | |
2016-12-31 FY2016 | — | $-1.49 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Cipher Pharmaceuticals Inc. (CPH.TO) measures how much investors pay for each dollar of the company's trailing earnings. CPH.TO's current PE ratio of 9.86x is calculated by dividing its stock price of $16.84 by its TTM earnings per share of $1.22.
Frequently asked questions
CPH.TO pe ratio · 6 questionsCPH.TO's current PE ratio is 9.86x as of 2026-06-08, based on a stock price of $16.84 and TTM EPS of $1.22. Data sourced from Financial Modeling Prep via CPH.TO's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Cipher Pharmaceuticals Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08